SLBT Stock: Dilution, SEC Filings & News – SL Science

SLBT SL Science Holding Ltd

Price$0.98

Company About

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company’s products include SL bio’s milk-derived exosome essence, SL bio’s tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

NASDAQ Global Market

Vol Avg.

65.36 K

Inst Own

0.000%

Float & OS

226.13 M / 560.76 M

Cash/Shr

$0.00017

Market Cap & Ev

549.54 M / -1.02 M

Short Interest

0.0%

Borrow Rate

151.6312%

Days to Cover

Research Report

Customize research

Recent Articles (8)

View All

SL Science Holding Limited Reports First Half 2026 Financial Results

Globe Newswire

Oct 26, 2026, 4:15 PM

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing γδ T Cells Target Chemotherapy-Resistant Glioblastoma

Globe Newswire

Sep 24, 2026, 8:00 AM

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

Globe Newswire

Sep 2, 2026, 4:10 PM

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

Globe Newswire

Aug 27, 2026, 8:00 AM

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of γδ T Cell Therapy in Glioblastoma

Globe Newswire

Aug 11, 2026, 8:00 AM

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Globe Newswire

Jul 17, 2026, 8:00 AM

SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma

Globe Newswire

Jul 10, 2026, 8:00 AM

SL Science Holding Limited Reports Full Year 2025 Financial Results

Globe Newswire

Jun 18, 2026, 5:13 PM

Recent Filings

View All

Type	Title	Date Released
3	Hung Chin-Sheng (Reporting)	Nov 6, 2026, 4:15 PM
4	Shen Ethan PhD (Reporting)	Nov 3, 2026, 4:15 PM
6-K	SL Science Holding Limited Announces Board and Executive Leadership Changes	Nov 3, 2026, 4:15 PM
6-K	SL Science Holding Limited Reports Unaudited Financial Results for the Period Ended June 30, 2026, Following Business Combination and PIPE Financing	Oct 26, 2026, 4:37 PM
S-8	Form S-8	Oct 9, 2026, 4:15 PM
SCHEDULE 13D/A	Wang Ching-Dong (Filed by)	Oct 1, 2026, 4:30 PM
4	Wang Ching-Dong (Reporting)	Oct 1, 2026, 4:30 PM
6-K	SL Science Holding Limited to Follow Cayman Islands Practice in Lieu of Certain Nasdaq Marketplace Rules	Sep 24, 2026, 4:05 PM
4	LAU JOHNSON SHUN-PONG (Reporting)	Sep 1, 2026, 4:45 PM
6-K	SL Science Holding Limited Announces Resignation of Vice President of Finance	Sep 1, 2026, 4:30 PM
6-K	SL Science Holding Limited Announces Change of Independent Registered Public Accounting Firm	Aug 27, 2026, 8:30 AM
424B3	Form 424B3	Aug 14, 2026, 9:20 AM

Earnings

No earnings availableNo calendar earnings available for SLBT

Related Healthcare stocks

All tickers

SL Science Holding Ltd SLBT

Related Healthcare stocks

Related Healthcare stocks